Drugs / AR101
AR101
also known as
PTAH · Peanut (Arachis hypogaea) Allergen Powder-dnfp · KBPA-101 · Palforzia · peanut allergen powder-dnfp
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00851435 | Feb 2008 → Jul 2009 | pneumonia | Kenta Biotech Ltd | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03682770 | Oct 2018 → Oct 2020 | food allergy | Regeneron Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT02198664 | Aug 2014 → Jan 2018 | food allergy | Aimmune Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01987817 | Feb 2014 → Jan 2015 | food allergy | Aimmune Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03292484 | Nov 2017 → Apr 2023 | food allergy | Aimmune Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03337542 | Oct 2017 → Sep 2019 | food allergy | Aimmune Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02993107 | Dec 2016 → May 2019 | food allergy | Aimmune Therapeutics, Inc. | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03736447 Comparator | Dec 2018 → Jul 2022 | food allergy | Aimmune Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03703791 Comparator | Oct → Nov 2018 | food allergy | Aimmune Therapeutics, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03201003 Comparator | Jun 2017 → Feb 2019 | food allergy | Aimmune Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03126227 Comparator | May 2017 → Aug 2018 | food allergy | Aimmune Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03201003 ↗ |
| Known as | KBPA-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00851435 ↗ |
| Known as | Palforzia | “oral immunotherapy with peanut (Arachis hypogaea) allergen powder-dnfp (PTAH; Palforzia®)” PMID 36915184 ↗ Mar 2023 |
| Known as | Peanut (Arachis hypogaea) Allergen Powder-dnfp | “Peanut (Arachis hypogaea) Allergen Powder-dnfp (PTAH)-formerly AR101-has been established in clinical trials” PMID 34320250 ↗ Sep 20211“oral immunotherapy with peanut (Arachis hypogaea) allergen powder-dnfp (PTAH; Palforzia®)” PMID 36915184 ↗ Mar 2023 |
| Known as | peanut allergen powder-dnfp | “the only approved treatment for children 4 to 17 years of age is peanut allergen powder-dnfp (PTAH) oral immunotherapy.” PMID 38320526 ↗ Oct 2023 |
| Known as | PTAH | “the only approved treatment for children 4 to 17 years of age is peanut allergen powder-dnfp (PTAH) oral immunotherapy.” PMID 38320526 ↗ Oct 20232“Peanut (Arachis hypogaea) Allergen Powder-dnfp (PTAH)-formerly AR101-has been established in clinical trials” PMID 34320250 ↗ Sep 2021 “oral immunotherapy with peanut (Arachis hypogaea) allergen powder-dnfp (PTAH; Palforzia®)” PMID 36915184 ↗ Mar 2023 |
| Modality | Monoclonal antibody | “KBPA-101, a monoclonal antibody” NCT00851435 ↗ |
| Route | Intravenous | “1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day” NCT00851435 ↗ |